Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline - Danaher (NYSE:DHR)

Danaher Raises 2025 Earnings Outlook @themotleyfool #stocks $DHR

Danaher's imperfect quarter is good enough for us to stay the course

Shares fluctuated between gains and losses in Tuesday's session.

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline - Danaher (NYSE:DHR)

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion.  The life science giant reported adjusted earnings of $1.80 per share, beating the consensus of $1.64. Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in low single digits year over year. Operating cash flow was $1.3 billion, and non-GAAP free cash fl…

California Life Sciences Rebound in 2024, Driving Innovation and Economic Output - The Registry

California’s life science industry regained momentum in 2024, reinforcing its position as a global leader in biotechnology, diagnostics and medical device innovation. According to the 2025 Biocom California Life Science Economic Impact Report, the sector produced $395.7 billion in total business output last year, supported $125.7 billion in labor income and employed approximately 1.15 million […] The post California Life Sciences Rebound in 2024…

Danaher Earnings: Strong Bioprocessing Growth Powers Q2 Beat, EPS Guidance Raised to $7.80

Danaher reports $1.80 EPS on $5.9B revenue, exceeding Q2 forecasts. Bioprocessing segment shows robust growth as company raises full-year outlook. See detailed metrics.